Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2011, Article ID 485063, 6 pages
http://dx.doi.org/10.4061/2011/485063
Review Article

Dopamine-Induced Nonmotor Symptoms of Parkinson's Disease

1Department of Neurology, The Ohio State University, Columbus, OH 43210, USA
2Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA

Received 15 October 2010; Accepted 14 February 2011

Academic Editor: Irena Rektorova

Copyright © 2011 Ariane Park and Mark Stacy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Fénelon, F. Mahieux, R. Huon, and M. Ziégler, “Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors,” Brain, vol. 123, part 4, pp. 733–745, 2000. View at Google Scholar · View at Scopus
  2. J. R. Sanchez-Ramos, R. Ortoll, and G. W. Paulson, “Visual hallucinations associated with Parkinson disease,” Archives of Neurology, vol. 53, no. 12, pp. 1265–1268, 1996. View at Google Scholar · View at Scopus
  3. K. M. Biglan, R. G. Holloway Jr., M. P. McDermott, and I. H. Richard, “Risk factors for somnolence, edema, and hallucinations in early Parkinson disease,” Neurology, vol. 69, no. 2, pp. 187–195, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. P. Pollak, F. Tison, O. Rascol et al., “Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 5, pp. 689–695, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. W. G. Ondo, R. Tintner, K. D. Voung, D. Lai, and G. Ringholz, “Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease,” Movement Disorders, vol. 20, no. 8, pp. 958–963, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. T. A. Zesiewicz, K. L. Sullivan, I. Arnulf et al., “Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, vol. 74, no. 11, pp. 924–931, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. M. Miyasaki, K. Shannon, V. Voon et al., “Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology,” Neurology, vol. 66, no. 7, pp. 996–1002, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. D. Weintraub, J. Koester, M. N. Potenza et al., “Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients,” Archives of Neurology, vol. 67, no. 5, pp. 589–595, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. Weintraub, A. D. Siderowf, M. N. Potenza et al., “Association of dopamine agonist use with impulse control disorders in Parkinson disease,” Archives of Neurology, vol. 63, no. 7, pp. 969–973, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. V. Voon, K. Hassan, M. Zurowski et al., “Prospective prevalence of pathologic gambling and medication association in Parkinson disease,” Neurology, vol. 66, no. 11, pp. 1750–1752, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. Antonini, E. Tolosa, Y. Mizuno, M. Yamamoto, and W. H. Poewe, “A reassessment of risks and benefits of dopamine agonists in Parkinson's disease,” The Lancet Neurology, vol. 8, no. 10, pp. 929–937, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. American Psychiatric Association, Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders : DSM-IV-TR, vol. 37, American Psychiatric Association, Washington, DC, USA, 4th edition, 2000.
  13. E. Driver-Dunckley, J. Samanta, and M. Stacy, “Pathological gambling associated with dopamine agonist therapy in Parkinson's disease,” Neurology, vol. 61, no. 3, pp. 422–423, 2003. View at Google Scholar · View at Scopus
  14. C. Lu, A. Bharmal, and O. Suchowersky, “Gambling and Parkinson disease,” Archives of Neurology, vol. 63, no. 2, p. 298, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. Cannas, P. Solla, G. L. Floris, G. Serra, P. Tacconi, and M. G. Marrosu, “Aberrant sexual behaviours in Parkinson's disease during dopaminergic treatment,” Journal of Neurology, vol. 254, no. 1, pp. 110–112, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. R. Ceravolo, D. Frosini, C. Rossi, and U. Bonuccelli, “Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management,” Parkinsonism and Related Disorders, vol. 15, supplement 4, pp. S111–S115, 2009. View at Publisher · View at Google Scholar
  17. D. Weintraub, “Impulse control disorders in Parkinson's disease: prevalence and possible risk factors,” Parkinsonism and Related Disorders, vol. 15, supplement 3, pp. S110–S113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. A. Christenson, R. J. Faber, M. De Zwaan et al., “Compulsive buying: descriptive characteristics and psychiatric comorbidity,” Journal of Clinical Psychiatry, vol. 55, no. 1, pp. 5–11, 1994. View at Google Scholar · View at Scopus
  19. J. M. Miyasaki, K. Al Hassan, A. E. Lang, and V. Voon, “Punding prevalence in Parkinson's disease,” Movement Disorders, vol. 22, no. 8, pp. 1179–1181, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. H. Evans, A. P. Strafella, D. Weintraub, and M. Stacy, “Impulsive and compulsive behaviors in Parkinson's disease,” Movement Disorders, vol. 24, no. 11, pp. 1561–1570, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. F. R. Pezzella, C. Colosimo, N. Vanacore et al., “Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease,” Movement Disorders, vol. 20, no. 1, pp. 77–81, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. A. H. Evans, R. Katzenschlager, D. Paviour et al., “Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome,” Movement Disorders, vol. 19, no. 4, pp. 397–405, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. D. A. Gallagher, S. S. O'Sullivan, A. H. Evans, A. J. Lees, and A. Schrag, “Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series,” Movement Disorders, vol. 22, no. 12, pp. 1757–1763, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. A. D. Lawrence, A. H. Evans, and A. J. Lees, “Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?” Lancet Neurology, vol. 2, no. 10, pp. 595–604, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. G. F. Koob and M. Le Moal, “Drug addiction, dysregulation of reward, and allostasis,” Neuropsychopharmacology, vol. 24, no. 2, pp. 97–129, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. G. Giovannoni, J. D. O'Sullivan, K. Turner, A. J. Manson, and A. J. L. Lees, “Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies,” Journal of Neurology Neurosurgery and Psychiatry, vol. 68, no. 4, pp. 423–428, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. A. H. Evans, N. Pavese, A. D. Lawrence et al., “Compulsive drug use linked to sensitized ventral striatal dopamine transmission,” Annals of Neurology, vol. 59, no. 5, pp. 852–858, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. J. G. Nutt, “Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa?” Movement Disorders, vol. 22, no. 1, pp. 1–9, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. S. Leu-Semenescu, E. Karroum, A. Brion, E. Konofal, and I. Arnulf, “Dopamine dysregulation syndrome in a patient with restless legs syndrome,” Sleep Medicine, vol. 10, no. 4, pp. 494–496, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. H. Evans, A. D. Lawrence, J. Potts, S. Appel, and A. J. Lees, “Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease,” Neurology, vol. 65, no. 10, pp. 1570–1574, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. V. Voon, T. Thomsen, J. M. Miyasaki et al., “Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease,” Archives of Neurology, vol. 64, no. 2, pp. 212–216, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. L. Silveira-Moriyama, A. H. Evans, R. Katzenschlager, and A. J. Lees, “Punding and dyskinesias,” Movement Disorders, vol. 21, no. 12, pp. 2214–2217, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. A. Thomas, L. Bonanni, F. Gambi, A. Di Iorio, and M. Onofrj, “Pathological gambling in parkinson disease is reduced by amantadine,” Annals of Neurology, vol. 68, no. 3, pp. 400–404, 2010. View at Publisher · View at Google Scholar · View at PubMed
  34. C. Ardouin, V. Voon, Y. Worbe et al., “Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation,” Movement Disorders, vol. 21, no. 11, pp. 1941–1946, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. F. Bandini, A. Primavera, M. Pizzorno, and L. Cocito, “Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 13, no. 6, pp. 369–371, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. S. Y. Lim, S. S. O'Sullivan, K. Kotschet et al., “Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease,” Journal of Clinical Neuroscience, vol. 16, no. 9, pp. 1148–1152, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. M. Stacy, “Managing late complications of Parkinson's disease,” Medical Clinics of North America, vol. 83, no. 2, pp. 469–481, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. R. L. Stowe, N. J. Ives, C. Clarke et al., “Dopamine agonist therapy in early Parkinson's disease,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD006564, 2008. View at Google Scholar
  39. D. S. Goldstein, “Orthostatic hypotension as an early finding in Parkinson's disease,” Clinical Autonomic Research, vol. 16, no. 1, pp. 46–54, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. C. Magerkurth, R. Schnitzer, and S. Braune, “Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life,” Clinical Autonomic Research, vol. 15, no. 2, pp. 76–82, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. G. Mostile and J. Jankovic, “Treatment of dysautonomia associated with Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, no. 3, pp. S224–S232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. W. Singer, P. Sandroni, T. L. Opfer-Gehrking et al., “Pyridostigmine treatment trial in neurogenic orthostatic hypotension,” Archives of Neurology, vol. 63, no. 4, pp. 513–518, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. R. Sakakibara, T. Odaka, Z. Lui et al., “Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson's disease and multiple system atrophy),” Movement Disorders, vol. 20, no. 2, pp. 261–262, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. J. F. Johanson and R. Ueno, “Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 11, pp. 1351–1361, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. R. Zangaglia, E. Martignoni, M. Glorioso et al., “Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study,” Movement Disorders, vol. 22, no. 9, pp. 1239–1244, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. W. H. Jost and K. Schimrigk, “Long-term results with cisapride in Parkinson's disease,” Movement Disorders, vol. 12, no. 3, pp. 423–425, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. Z. Liu, R. Sakakibara, T. Odaka et al., “Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, amerliorates constipation in Parkinsonian patients,” Movement Disorders, vol. 20, no. 6, pp. 680–686, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. K. L. Sullivan, J. F. Staffetti, R. A. Hauser, P. B. Dunne, and T. A. Zesiewicz, “Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease,” Movement Disorders, vol. 21, no. 1, pp. 115–116, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. K. Sadjadpour, “Pyridostigmine bromide and constipation in Parkinson's disease,” Journal of the American Medical Association, vol. 249, no. 9, pp. 1148–1149, 1983. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Albanese, G. Maria, A. Bentivoglio, G. Brisinda, E. Cassetta, and P. Tonali, “Severe constipation in Parkinson's disease relieved by botulinum toxin,” Movement Disorders, vol. 12, no. 5, pp. 764–766, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. R. A. Pinto and D. R. Sands, “Surgery and sacral nerve stimulation for constipation and fecal incontinence,” Gastrointestinal Endoscopy Clinics of North America, vol. 19, no. 1, pp. 83–116, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. L. L. Edwards, E. M. M. Quigley, R. K. Harned, R. Hofman, and R. F. Pfeiffer, “Defecatory function in Parkinson's disease: response to apomorphine,” Annals of Neurology, vol. 33, no. 5, pp. 490–493, 1993. View at Google Scholar · View at Scopus
  53. H. Honig, A. Antonini, P. Martinez-Martin et al., “Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life,” Movement Disorders, vol. 24, no. 10, pp. 1468–1474, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. M. Stacy, “Sleep disorders in Parkinson's disease: epidemiology and management,” Drugs and Aging, vol. 19, no. 10, pp. 733–739, 2002. View at Google Scholar · View at Scopus
  55. C. L. Comella, “Sleep disturbances in Parkinson's disease,” Current Neurology and Neuroscience Reports, vol. 3, no. 2, pp. 173–180, 2003. View at Google Scholar · View at Scopus
  56. D. Verbaan, S. M. Van Rooden, M. Visser, J. Marinus, and J. J. Van Hilten, “Nighttime sleep problems and daytime sleepiness in Parkinson's disease,” Movement Disorders, vol. 23, no. 1, pp. 35–41, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. H. Brunner, T. C. Wetter, B. Hoegl, A. Yassouridis, C. Trenkwalder, and E. Friess, “Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment,” Movement Disorders, vol. 17, no. 5, pp. 928–933, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. M. D. Gjerstad, G. Alves, T. Wentzel-Larsen, D. Aarsland, and J. P. Larsen, “Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?” Neurology, vol. 67, no. 5, pp. 853–858, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. S. Frucht, J. D. Rogers, P. E. Greene, M. F. Gordon, and S. Fahn, “Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole,” Neurology, vol. 52, no. 9, pp. 1908–1910, 1999. View at Google Scholar · View at Scopus
  60. R. Manni, M. Terzaghi, I. Sartori, F. Mancini, and C. Pacchetti, “Dopamine agonists and sleepiness in PD: review of the literature and personal findings,” Sleep Medicine, vol. 5, no. 2, pp. 189–193, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. S. Paus, H. M. Brecht, J. Köster, G. Seeger, T. Klockgether, and U. Wüllner, “Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease,” Movement Disorders, vol. 18, no. 6, pp. 659–667, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. P. Dušek, J. Bušková, E. Růžička et al., “Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in parkinson disease,” Clinical Neuropharmacology, vol. 33, no. 4, pp. 186–190, 2010. View at Publisher · View at Google Scholar · View at PubMed
  63. E. Miller and H. A. Nieburg, “Amphetamines. Valuable adjunct in treatment of Parkinsonism,” New York State Journal of Medicine, vol. 73, no. 22, pp. 2657–2661, 1973. View at Google Scholar · View at Scopus
  64. C. H. Adler, J. N. Caviness, J. G. Hentz, M. Lind, and J. Tiede, “Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease,” Movement Disorders, vol. 18, no. 3, pp. 287–293, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. W. G. Ondo, T. Perkins, T. Swick et al., “Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study,” Archives of Neurology, vol. 65, no. 10, pp. 1337–1340, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. G. A. Dowling, J. Mastick, E. Colling, J. H. Carter, C. M. Singer, and M. J. Aminoff, “Melatonin for sleep disturbances in Parkinson's disease,” Sleep Medicine, vol. 6, no. 5, pp. 459–466, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. N. Hjort, K. Øtergaard, and E. Dupont, “Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus,” Movement Disorders, vol. 19, no. 2, pp. 196–199, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus